Loading...
XTAE
BARI
Market cap326mUSD
Jun 02, Last price  
7,058.00ILS
Name

Panaxia Labs Israel Ltd

Chart & Performance

D1W1MN
XTAE:BARI chart
P/E
P/S
53.95
EPS
Div Yield, %
Shrs. gr., 5y
-55.07%
Rev. gr., 5y
179.52%
Revenues
20m
-50.31%
0231,000016,690,00060,747,00083,599,00039,419,00019,588,000
Net income
-13m
L-69.02%
-5,131,000-2,277,0002,732,000-81,343,000-35,901,000-21,378,000-43,270,000-13,404,000
CFO
-563k
L-93.75%
-761,000-2,019,000-1,696,000-12,039,000-34,081,000-47,923,000-9,008,000-563,000
Dividend
Jun 03, 2012107.388 ILS/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Panaxia Labs Israel Ltd provides pharmaceutical solutions for patients and physicians in Israel and internationally. It offers pharma-grade smokeless cannabis products, such as oral tablets, orodispersible tablets, sublingual tablets, oral oils, sublingual drops, solution for inhalation, pastilles, topicals, suppositories, and cannabis extracts in ethanol under the NAXIVA – PANAXOL, NAXIVA-PANAXOL-ONKO, PANAXIR SENSE, PANAXIR, Axiban, Tikva, Ultra Health, and Salus brands. The company was incorporated in 2005 and is based in Lod, Israel.
IPO date
Aug 10, 2006
Employees
59
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT